DMIIU — Drugs Made In America Acquisition II Income Statement
0.000.00%
Last trade - 00:00- $654.44m
- $654.12m
Annual income statement for Drugs Made In America Acquisition II, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2024 December 31st | |
|---|---|
| Period Length: | 12 M |
| Source: | PROSPECTUS |
| Standards: | USG |
| Status: | Final |
| Total Revenue | 0 |
| Selling / General / Administrative Expenses | |
| Total Operating Expenses | 0.303 |
| Operating Profit | -0.303 |
| Net Income Before Taxes | -0.303 |
| Net Income After Taxes | -0.303 |
| Net Income Before Extraordinary Items | |
| Net Income | -0.303 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |
| Income Available to Common Shareholders Including Extraordinary Items | |
| Diluted Net Income | -0.303 |
| Diluted Weighted Average Shares | |
| Basic EPS Including Extraordinary Items | |
| Diluted EPS Including Extraordinary Items | |
| Diluted EPS Excluding Extraordinary Items | |
| Normalised Income Before Taxes | |
| Normalised Income After Taxes | |
| Normalised Income Available to Common Shareholders | |
| Diluted Normalised EPS | -0.006 |